Scientific article
English

Haematotoxicity of Craniospinal Radiochemotherapy for Metastatic Paediatric High-Grade Glioma

Published inClinical oncology, vol. 48, 103956
Publication date2025-12
First online date2025-10-11
Abstract

Aims: Paediatric high-grade gliomas (pedHGGs) have a dismal prognosis, often characterised by early and diffuse disease progression. Novel treatment approaches are urgently needed to improve outcomes. The upcoming SIOPE-HGG (High Grade Glioma)-01 trial will investigate upfront craniospinal radiochemotherapy (CSI-RCT) for newly diagnosed, nonmetastatic diffuse midline glioma/diffuse intrinsic pontine glioma (DMG/DIPG). As CSI-RCT is frequently avoided due to concerns over haematotoxicity, real-world feasibility data are critically needed.

Materials and methods: We retrospectively assessed haematological toxicity in 19 patients (aged 3-21 years) with metastatic pedHGG treated with CSI-RCT within the hirn tumor glioblastoma trial (HIT-HGG) and hospital in trial-glioblastoma (HIT-GBM) trial programmes (2002-2024). All patients received craniospinal irradiation (median dose: 35.2 Gy) using photon- or proton-based techniques, with concurrent chemotherapy: temozolomide (TMZ; n = 14) or PEI (cisplatin, etoposide, ifosfamide; n = 5). Haematological toxicities were graded according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

Results: Grade 3 to 4 haematotoxicity was observed in 7 of 19 patients (36.8%). Chemotherapy was discontinued in two cases-one due to TMZ-induced aplastic anaemia (TIAA) and another due to thrombocytopaenia. The remaining patients tolerated full-dose CSI-RCT with manageable side effects, and no unplanned radiotherapy interruptions occurred. The haematotoxicity rate was comparable to or lower than previous reports, indicating that CSI-RCT is feasible with appropriate monitoring and management.

Conclusion: This is the largest cohort to date assessing haematological toxicity of upfront CSI-RCT in metastatic pedHGG. Despite notable haematotoxicity, treatment was largely feasible and well-tolerated. These findings support the integration of CSI-RCT into future clinical trials for newly diagnosed DMG/DIPG and provide a foundation for the upcoming SIOPE HGG-01 trial. Proton therapy may further reduce toxicity and warrants prospective evaluation.

Keywords
  • Craniospinal radiochemotherapy
  • Haematotoxicity
  • Paediatric high-grade glioma
  • Humans
  • Child
  • Child, Preschool
  • Adolescent
  • Male
  • Female
  • Chemoradiotherapy / adverse effects
  • Chemoradiotherapy / methods
  • Young Adult
  • Retrospective Studies
  • Glioma / pathology
  • Glioma / therapy
  • Craniospinal Irradiation / adverse effects
  • Craniospinal Irradiation / methods
  • Brain Neoplasms / pathology
  • Brain Neoplasms / therapy
  • Temozolomide / adverse effects
  • Temozolomide / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Citation (ISO format)
VALENTINI, C et al. Haematotoxicity of Craniospinal Radiochemotherapy for Metastatic Paediatric High-Grade Glioma. In: Clinical oncology, 2025, vol. 48, p. 103956. doi: 10.1016/j.clon.2025.103956
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
Journal ISSN0936-6555
12views
0downloads

Technical informations

Creation22/11/2025 18:08:52
First validation09/01/2026 13:48:03
Update09/01/2026 13:48:03
Status update09/01/2026 13:48:03
Last indexation09/01/2026 13:48:04
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack